Kangzhi Pharmaceuticals: Net loss of 54.08 million yuan in the first half of 2025.

Kangzhi Pharmaceutical announced that its operating income in the first half of 2025 was 232 million yuan, a year-on-year increase of 5.56%. The net loss was 54.08 million yuan, compared to a net loss of 101 million yuan in the same period last year. The company plans not to distribute cash dividends, bonus shares, or increase share capital through capital reserves.